Becton, Dickinson and Company $BDX Stock: Vest Financial LLC Grows Position

Vest Financial LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 356,140 shares of the medical instruments supplier’s stock after buying an additional 46,239 shares during the period. Vest Financial LLC owned 0.13% of Becton, Dickinson and Company worth $63,749,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $3,721,533,000. Bank of America Corp DE acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at $474,993,000. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 15.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Becton, Dickinson and Company in the 2nd quarter valued at $247,372,000. Finally, Deutsche Bank AG acquired a new stake in Becton, Dickinson and Company during the 2nd quarter worth $204,226,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.3%

NYSE:BDX opened at $194.29 on Thursday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $195.99. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock’s 50 day simple moving average is $184.73 and its 200-day simple moving average is $164.54. The firm has a market cap of $53.53 billion, a P/E ratio of 58.52, a PEG ratio of 13.07 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company earned $3.68 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Analyst Ratings Changes

Several research analysts have issued reports on BDX shares. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. TD Cowen upped their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Finally, Bank of America increased their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $185.07.

Insiders Place Their Bets

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 6,906 shares of company stock worth $1,265,855. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.